← Back to Patent Explorer
US4935465A Expired / Lapsed US ⏱️ 0.0 years remaining

Conjugates of pharmaceutically useful proteins

Assignee: Adprotech PLC
•
Filing: 1985-11-27
•
Granted: 1990-06-19
•
Expires: 2005-11-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A conjugate comprising a pharmaceutically useful protein linked to at least one water-soluble polymer by means of a reversible linking group.

Inventors

  • 👤 Andrew J. Garman

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 11:38
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/48; A61K38/49; A61K38/17; A61K38/38; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 208 words
A conjugate of formula (II): ##STR12## where X is a pharmaceutically useful protein and the NH moiety is derived from a protein amino group in X; and either: (i) R1 and R 2 are each a non-polymeric organic group or a group of formula --R 3 --P wherein P is a water-soluble polymer selected from the group consisting of polyethylene glycol, polypropylene glycol and methoxy polyethylene glycol and R 3 is a bridging group selected from the group consisting of straight or branched C 1-10 aliphatic hydrocarbon chains and straight or branched C 1-10 aliphatic hydrocarbon chains interrupted or terminated by an amide moiety, an ester moiety or at least one hetero atom selected from oxygen, sulphur or nitrogen, said moiety being unsubstituted or substituted by C 1-16 alkyl; or (ii) R 1 and R 2 together are C 3-5 polymethylene to complete a 5- to 7-membered alicyclic ring or together complete an aromatic ring, wherein the alicyclic or aromatic ring is substituted by groups R 4 and R 5 which are each of non-polymeric organic group or a group of formula --R 3 --P; provided that at lease one of RI and R 2 or of R 4 and R 5 is a group --R 3 --P.
Claim 2
Dependent Claim 208 words
A conjugate of formula (II): ##STR12## where X is a pharmaceutically useful protein and the NH moiety is derived from a protein amino group in X; and either: (i) R1 and R 2 are each a non-polymeric organic group or a group of formula --R 3 --P wherein P is a water-soluble polymer selected from the group consisting of polyethylene glycol, polypropylene glycol and methoxy polyethylene glycol and R 3 is a bridging group selected from the group consisting of straight or branched C 1-10 aliphatic hydrocarbon chains and straight or branched C 1-10 aliphatic hydrocarbon chains interrupted or terminated by an amide moiety, an ester moiety or at least one hetero atom selected from oxygen, sulphur or nitrogen, said moiety being unsubstituted or substituted by C 1-16 alkyl; or (ii) R 1 and R 2 together are C 3-5 polymethylene to complete a 5- to 7-membered alicyclic ring or together complete an aromatic ring, wherein the alicyclic or aromatic ring is substituted by groups R 4 and R 5 which are each of non-polymeric organic group or a group of formula --R 3 --P; provided that at lease one of RI and R 2 or of R 4 and R 5 is a group --R 3 --P.
Claim 3
Dependent Claim 19 words
A conjugate according to claim 1 in which the pharmaceutically useful protein is a fibrinolytic enzyme or pro-enzyme thereof.
Claim 4
Dependent Claim 24 words
A conjugate according to claim 1, wherein one of R 1 and R 2 is a group P--CH 2 --and the other is methyl.
Claim 5
Dependent Claim 14 words
A conjugate according to claim 1, wherein the water soluble polymer is methoxypolyethylene glycol.
Claim 6
Dependent Claim 17 words
A conjugate according to claim 1, wherein the pharmaceutically useful protein is tissue plasminogen activator or urokinase.
Claim 7
Dependent Claim 45 words
A process for preparing a conjugate according to claim 1 which process comprises reacting a pharmaceutically useful protein with a water-soluble polymer-containing regent comprising a group which is capable of reacting with a protein amino group or derivative thereof, to form a reversible linking group.
Claim 8
Dependent Claim 43 words
A conjugate according to claim 1, wherein PR 3 --is P(CH 2 ) n --, PO(CH 2 ) n O--, P(CH 3 )CH--, P(CH 3 ) 2 C--, PO(CH 3 )CH-- or PO(CH 3 ) 2 C-- where n is 1 to 6.
Claim 9
Dependent Claim 17 words
2[ω-MethoxypolyethyIeneglycoxymethylene]-3-methylmaleyl-human serum albumin, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-human serum albumin, [ω -methoxypolyethyleneglycoxymethylene]-3-methylmaleyl-urokinase, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-urokinase, 2-[ω-methoxypolyethyleneglycoxymethylene]-3- methyl-maleyl-tissue plasminogen activator or 2-methyl-3-[ω-methoxypolyethylenegIycoxy-methylene]-maleyl-tissue plasminogen activator.
Claim 10
Dependent Claim 17 words
2[ω-MethoxypolyethyIeneglycoxymethylene]-3-methylmaleyl-human serum albumin, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-human serum albumin, [ω -methoxypolyethyleneglycoxymethylene]-3-methylmaleyl-urokinase, 2-methyl-3-[ω-methoxypolyethyleneglycoxy-methylene]-maleyl-urokinase, 2-[ω-methoxypolyethyleneglycoxymethylene]-3- methyl-maleyl-tissue plasminogen activator or 2-methyl-3-[ω-methoxypolyethylenegIycoxy-methylene]-maleyl-tissue plasminogen activator.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1993-06-18 1993-12-18 1994-06-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1997-06-18 1997-12-18 1998-06-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2001-06-18 2001-12-18 2002-06-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag